$CDXS
CODEXIS, INC.

2022 Q3 Form 10-Q Financial Statement

#000120037522000032 Filed on August 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $34.47M $38.41M $35.34M
YoY Change -6.25% 50.89% 95.98%
Cost Of Revenue $9.786M $11.27M $8.521M
YoY Change 42.51% 161.0% 102.02%
Gross Profit $24.68M $27.14M $26.82M
YoY Change -17.45% 28.39% 94.14%
Gross Profit Margin 71.61% 70.66% 75.89%
Selling, General & Admin $13.50M $10.66M $15.71M
YoY Change 0.69% -16.72% 37.79%
% of Gross Profit 54.69% 39.27% 58.56%
Research & Development $21.82M $19.09M $19.50M
YoY Change 43.89% 48.83% 68.52%
% of Gross Profit 88.4% 70.35% 72.71%
Depreciation & Amortization $1.405M $1.341M $1.215M
YoY Change 82.94% 87.29% 84.37%
% of Gross Profit 5.69% 4.94% 4.53%
Operating Expenses $35.32M $29.75M $35.21M
YoY Change 23.62% 16.1% 53.27%
Operating Profit -$10.64M -$2.609M -$8.386M
YoY Change -899.7% -41.84% -8.4%
Interest Expense $436.0K $140.0K $42.00K
YoY Change 963.41% -32.04% -76.67%
% of Operating Profit
Other Income/Expense, Net $216.0K -$63.00K -$3.000K
YoY Change -78.03% -373.91% -96.59%
Pretax Income -$9.984M -$2.532M -$8.347M
YoY Change -524.13% -40.52% -7.93%
Income Tax $8.000K $108.0K $9.000K
% Of Pretax Income
Net Earnings -$9.992M -$2.640M -$8.356M
YoY Change -545.28% -38.1% -7.85%
Net Earnings / Revenue -28.99% -6.87% -23.64%
Basic Earnings Per Share -$0.15 -$0.04 -$0.13
Diluted Earnings Per Share -$0.15 -$0.04 -$0.13
COMMON SHARES
Basic Shares Outstanding 65.49M shares 65.29M shares 65.10M shares
Diluted Shares Outstanding 65.43M shares 65.29M shares 65.10M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $108.7M $90.11M $94.26M
YoY Change -8.81% -31.1% -33.05%
Cash & Equivalents $108.7M $90.10M $94.30M
Short-Term Investments
Other Short-Term Assets $5.910M $4.531M $4.933M
YoY Change 10.1% 8.84% 23.33%
Inventory $1.623M $1.718M $1.560M
Prepaid Expenses
Receivables $29.78M $48.92M $44.12M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $146.0M $145.3M $144.9M
YoY Change -16.15% -15.73% -16.53%
LONG-TERM ASSETS
Property, Plant & Equipment $23.32M $23.69M $23.47M
YoY Change 44.62% 110.95% 125.8%
Goodwill $3.200M $3.200M $3.200M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $20.51M $19.30M $19.00M
YoY Change 60.7% 462.74% 691.75%
Other Assets $208.0K $224.0K $257.0K
YoY Change -23.25% -25.58% 3.21%
Total Long-Term Assets $89.29M $89.69M $90.41M
YoY Change 67.09% 124.69% 134.17%
TOTAL ASSETS
Total Short-Term Assets $146.0M $145.3M $144.9M
Total Long-Term Assets $89.29M $89.69M $90.41M
Total Assets $235.3M $235.0M $235.3M
YoY Change 3.4% 10.67% 10.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.621M $2.015M $1.949M
YoY Change -20.12% -36.31% -45.39%
Accrued Expenses $12.99M $12.93M $14.17M
YoY Change -18.43% 42.41% 48.93%
Deferred Revenue $1.602M $2.230M $1.604M
YoY Change -34.59% -3.59% -15.45%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $31.91M $30.01M $29.50M
YoY Change -4.7% 24.59% 30.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.356M $1.340M $1.326M
YoY Change 29.02% 3.96% 3.84%
Total Long-Term Liabilities $1.356M $1.340M $1.326M
YoY Change 29.02% 3.96% 3.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.91M $30.01M $29.50M
Total Long-Term Liabilities $1.356M $1.340M $1.326M
Total Liabilities $81.16M $75.51M $76.64M
YoY Change 38.74% 52.43% 58.24%
SHAREHOLDERS EQUITY
Retained Earnings -$408.7M -$398.7M -$396.1M
YoY Change 8.26% 4.99% 5.48%
Common Stock $6.000K $6.000K $6.000K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $154.1M $159.5M $158.6M
YoY Change
Total Liabilities & Shareholders Equity $235.3M $235.0M $235.3M
YoY Change 3.4% 10.67% 10.89%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$9.992M -$2.640M -$8.356M
YoY Change -545.28% -38.1% -7.85%
Depreciation, Depletion And Amortization $1.405M $1.341M $1.215M
YoY Change 82.94% 87.29% 84.37%
Cash From Operating Activities $19.73M -$2.181M -$11.19M
YoY Change -10378.12% -73.71% 73.7%
INVESTING ACTIVITIES
Capital Expenditures -$1.310M -$1.941M $5.089M
YoY Change -67.28% 8.19% 99.57%
Acquisitions
YoY Change
Other Investing Activities $1.000K -$279.0K -$4.993M
YoY Change -100.01% -55.07% -25065.0%
Cash From Investing Activities -$1.309M -$2.220M -$10.08M
YoY Change -88.1% -8.07% 298.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 133.0K 233.0K -$1.280M
YoY Change -84.68% -48.57% -7629.41%
NET CHANGE
Cash From Operating Activities 19.73M -2.181M -$11.19M
Cash From Investing Activities -1.309M -2.220M -$10.08M
Cash From Financing Activities 133.0K 233.0K -$1.280M
Net Change In Cash 18.56M -4.168M -$22.55M
YoY Change -279.81% -59.36% 151.76%
FREE CASH FLOW
Cash From Operating Activities $19.73M -$2.181M -$11.19M
Capital Expenditures -$1.310M -$1.941M $5.089M
Free Cash Flow $21.04M -$240.0K -$16.28M
YoY Change 452.05% -96.31% 81.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001200375
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P6M
CY2022Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2022Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2022Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34705
dei Entity Registrant Name
EntityRegistrantName
Codexis, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
71-0872999
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Penobscot Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94063
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
421-8100
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
CDXS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
65494096 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90113000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116797000 usd
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
546000 usd
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
579000 usd
CY2022Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
29200000 usd
CY2021Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
24953000 usd
CY2022Q2 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
11287000 usd
CY2021Q4 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
4557000 usd
CY2022Q2 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
8543000 usd
CY2021Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
8558000 usd
CY2022Q2 us-gaap Notes Receivable Gross
NotesReceivableGross
49030000 usd
CY2021Q4 us-gaap Notes Receivable Gross
NotesReceivableGross
38068000 usd
CY2022Q2 cdxs Allowance For Credit Loss Current
AllowanceForCreditLossCurrent
109000 usd
CY2021Q4 cdxs Allowance For Credit Loss Current
AllowanceForCreditLossCurrent
416000 usd
CY2022Q2 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
48921000 usd
CY2021Q4 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
37652000 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
1718000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
1160000 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3985000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5700000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
145283000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
161888000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1520000 usd
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1519000 usd
CY2022Q2 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
19302000 usd
CY2021Q4 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
14002000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
41706000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44095000 usd
CY2022Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0 usd
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
17000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23694000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21345000 usd
CY2022Q2 us-gaap Goodwill
Goodwill
3241000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
3241000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
224000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
276000 usd
CY2022Q2 us-gaap Assets
Assets
234970000 usd
CY2021Q4 us-gaap Assets
Assets
246383000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2015000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2995000 usd
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7732000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11119000 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12934000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12578000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5103000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4093000 usd
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2230000 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2586000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
30014000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33371000 usd
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3151000 usd
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3749000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
41006000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
43561000 usd
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1340000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1311000 usd
CY2022Q2 us-gaap Liabilities
Liabilities
75511000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
81992000 usd
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65494000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65494000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65109000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65109000 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
558147000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
552083000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-398694000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-387698000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
159459000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
164391000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
234970000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
246383000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38406000 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25453000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73746000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
43485000 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11270000 usd
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4318000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
19791000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8536000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19089000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12826000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38590000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24397000 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10656000 usd
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12795000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
26360000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24193000 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
41015000 usd
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
29939000 usd
us-gaap Costs And Expenses
CostsAndExpenses
84741000 usd
us-gaap Costs And Expenses
CostsAndExpenses
57126000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2609000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4486000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-10995000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-13641000 usd
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
140000 usd
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
206000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
182000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
382000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-63000 usd
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
23000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-66000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-63000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2532000 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4257000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10879000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13322000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
108000 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
117000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2640000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-4265000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10996000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13333000 usd
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65288000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65288000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64434000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64434000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65193000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65193000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64363000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64363000 shares
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
158635000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
251000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3174000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
57000 usd
CY2022Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
18000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2640000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
159459000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
163739000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
455000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2779000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
65000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-4265000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
162773000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
164391000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
432000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6951000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
118000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1437000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10996000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
159459000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
170103000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1678000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5405000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
126000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1206000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13333000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
162773000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10996000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13333000 usd
us-gaap Depreciation
Depreciation
2556000 usd
us-gaap Depreciation
Depreciation
1375000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2406000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1309000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7069000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5531000 usd
cdxs Allowance For Credit Loss Period Increase Decrease
AllowanceForCreditLossPeriodIncreaseDecrease
307000 usd
cdxs Allowance For Credit Loss Period Increase Decrease
AllowanceForCreditLossPeriodIncreaseDecrease
0 usd
us-gaap Other Noncash Income
OtherNoncashIncome
245000 usd
us-gaap Other Noncash Income
OtherNoncashIncome
477000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-27000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-318000 usd
us-gaap Increase Decrease In Finance Receivables
IncreaseDecreaseInFinanceReceivables
10962000 usd
us-gaap Increase Decrease In Finance Receivables
IncreaseDecreaseInFinanceReceivables
7521000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
558000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
113000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1811000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
170000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-958000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
436000 usd
cdxs Increase Decrease In Employee Related Liabilities And Other Accrued Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilitiesAndOtherAccruedLiabilities
-81000 usd
cdxs Increase Decrease In Employee Related Liabilities And Other Accrued Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilitiesAndOtherAccruedLiabilities
404000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2527000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1314000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-710000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
264000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13367000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14735000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7030000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4344000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
28000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
29000 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
5300000 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
630000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12302000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4945000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
432000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1679000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
42000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1437000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1206000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1047000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
473000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26716000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-19207000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
118895000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
150817000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92179000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
131610000 usd
us-gaap Interest Paid Net
InterestPaidNet
12000 usd
us-gaap Interest Paid Net
InterestPaidNet
3000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
409000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
338000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90113000 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
129506000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2066000 usd
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2104000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92179000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
131610000 usd
us-gaap Nature Of Operations
NatureOfOperations
Description of Business<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In these notes to the unaudited condensed consolidated financial statements, the “Company,” “we,” “us,” and “our” refers to Codexis, Inc. and its subsidiaries on a consolidated basis.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We discover, develop and sell enzymes and other proteins that deliver value to our clients in a growing set of industries to commercialize an increasing number of novel enzymes, both as proprietary Codexis products and in partnership with our customers.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report our financial results based on two reportable segments: Performance Enzymes and Novel Biotherapeutics. The segment information aligns with how the chief operating decision maker (CODM), who is our Chief Executive Officer (CEO), reviews and manages the business.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Update Regarding COVID-19</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks and uncertainties as a result of the current COVID-19 pandemic. The COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, communities and business operations, as well as the U.S. economy and other economies worldwide. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain and may not be accurately predicted, including the duration and severity of the pandemic, the prevalence of more contagious and or virulent variants, and the extent and severity of the impact on our customers, new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we and our collaboration partners have been able to continue to supply our enzymes to our customers worldwide. However, we are dependent on our manufacturing and logistics partners and consequently, disruptions in operations of our partners and customers may affect our ability to supply enzymes to our customers. Furthermore, our ability to provide future R&amp;D services may continue to be impacted as a result of governmental orders ("Orders") and any disruptions in operations of our customers with whom we collaborate. We believe that these disruptions have had a minimal impact on revenue for the three and six months ended June 30, 2022. The extent to which the pandemic may impact our business operations and operating results will continue to remain highly dependent on future developments, which are uncertain and cannot be predicted with confidence. Should these disruptions escalate in the future, they may negatively and materially impact our business. results of operations and financial condition.</span></div>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
43485000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73746000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition, inventories, valuation of equity investments, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, and may not be accurately predicted, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers, markets and economies.</span></div>
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38406000 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25453000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38406000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38406000 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25453000 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25453000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73746000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
43485000 usd
CY2022Q2 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
11287000 usd
cdxs Non Marketable Debt Securities Without Readily Determinable Fair Value Annual Amount
NonMarketableDebtSecuritiesWithoutReadilyDeterminableFairValueAnnualAmount
0 usd
CY2021Q4 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
4557000 usd
CY2022Q2 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
8543000 usd
CY2021Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
8558000 usd
CY2022Q2 us-gaap Capitalized Contract Cost Net Current
CapitalizedContractCostNetCurrent
36000 usd
CY2021Q4 us-gaap Capitalized Contract Cost Net Current
CapitalizedContractCostNetCurrent
56000 usd
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
5381000 usd
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
6335000 usd
us-gaap Contract With Customer Asset Credit Loss Expense
ContractWithCustomerAssetCreditLossExpense
0 usd
us-gaap Contract With Customer Asset Credit Loss Expense
ContractWithCustomerAssetCreditLossExpense
0 usd
CY2021Q2 us-gaap Contract With Customer Asset Credit Loss Expense
ContractWithCustomerAssetCreditLossExpense
0 usd
CY2022Q2 us-gaap Contract With Customer Asset Credit Loss Expense
ContractWithCustomerAssetCreditLossExpense
0 usd
CY2022Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
441000 usd
CY2021Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1239000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1413000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1391000 usd
CY2022Q2 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
-298000 usd
CY2021Q2 cdxs Non Marketable Debt Securities Without Readily Determinable Fair Value Annual Amount
NonMarketableDebtSecuritiesWithoutReadilyDeterminableFairValueAnnualAmount
0 usd
CY2021Q2 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
4306000 usd
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
-29000 usd
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
4336000 usd
CY2022Q2 cdxs Contractwith Customer Liability New Activities Performance Obligation Satisfied Revenue Recognition
ContractwithCustomerLiabilityNewActivitiesPerformanceObligationSatisfiedRevenueRecognition
38263000 usd
CY2021Q2 cdxs Contractwith Customer Liability New Activities Performance Obligation Satisfied Revenue Recognition
ContractwithCustomerLiabilityNewActivitiesPerformanceObligationSatisfiedRevenueRecognition
19908000 usd
cdxs Contractwith Customer Liability New Activities Performance Obligation Satisfied Revenue Recognition
ContractwithCustomerLiabilityNewActivitiesPerformanceObligationSatisfiedRevenueRecognition
72362000 usd
cdxs Contractwith Customer Liability New Activities Performance Obligation Satisfied Revenue Recognition
ContractwithCustomerLiabilityNewActivitiesPerformanceObligationSatisfiedRevenueRecognition
37758000 usd
CY2022Q2 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
38406000 usd
CY2021Q2 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
25453000 usd
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
73746000 usd
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
43485000 usd
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1000000 usd
CY2020Q4 us-gaap Convertible Debt
ConvertibleDebt
1300000 usd
CY2021Q2 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
200000 usd
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
300000 usd
CY2022Q2 cdxs Non Marketable Debt Securities Without Readily Determinable Fair Value Annual Amount
NonMarketableDebtSecuritiesWithoutReadilyDeterminableFairValueAnnualAmount
0 usd
cdxs Non Marketable Debt Securities Without Readily Determinable Fair Value Annual Amount
NonMarketableDebtSecuritiesWithoutReadilyDeterminableFairValueAnnualAmount
0 usd
CY2022Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1024000 usd
CY2022Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1359000 usd
CY2022Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
115000 usd
CY2022Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
2883000 usd
CY2022Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
5381000 usd
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1400000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23694000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21345000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90100000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116800000 usd
CY2022Q2 us-gaap Depreciation
Depreciation
1341000 usd
CY2021Q2 us-gaap Depreciation
Depreciation
716000 usd
CY2022Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
49000 usd
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
49000 usd
CY2022Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
73000 usd
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
65000 usd
CY2022Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1596000 usd
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1046000 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
1718000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
1160000 usd
CY2022Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1400000 usd
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
61813000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
57227000 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
38119000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
35882000 usd
us-gaap Depreciation
Depreciation
2556000 usd
us-gaap Depreciation
Depreciation
1375000 usd
CY2022Q2 us-gaap Goodwill
Goodwill
3200000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
3200000 usd
CY2022Q2 us-gaap Purchase Obligation
PurchaseObligation
8292000 usd
CY2021Q4 us-gaap Purchase Obligation
PurchaseObligation
6755000 usd
CY2022Q2 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
4113000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
5147000 usd
CY2022Q2 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
529000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
676000 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12934000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12578000 usd
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1829000 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
3231000 usd
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2844000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7069000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5531000 usd
CY2022Q2 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
77300 sqft
CY2022Q2 cdxs Lessee Operating Lease Option To Extend Number
LesseeOperatingLeaseOptionToExtendNumber
1 renewal_option
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
3231000 usd
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2844000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7069000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5531000 usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
174600 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
212631 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.47
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.03
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
400000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1700000 usd
CY2022Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
500000 usd
CY2021Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
400000 usd
CY2022Q2 cdxs Finance Lease Cost
FinanceLeaseCost
0 usd
CY2021Q2 cdxs Finance Lease Cost
FinanceLeaseCost
27000 usd
cdxs Finance Lease Cost
FinanceLeaseCost
18000 usd
cdxs Finance Lease Cost
FinanceLeaseCost
53000 usd
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1033000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
3660000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
2065000 usd
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
10000 usd
CY2021Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
10000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
40000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
10000 usd
CY2022Q2 us-gaap Lease Cost
LeaseCost
1839000 usd
CY2021Q2 us-gaap Lease Cost
LeaseCost
1070000 usd
us-gaap Lease Cost
LeaseCost
3718000 usd
us-gaap Lease Cost
LeaseCost
2128000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y6M
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.054
us-gaap Operating Lease Payments
OperatingLeasePayments
2817000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
2093000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3688000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
7568000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7783000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8004000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8232000 usd
CY2022Q2 cdxs Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
20706000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
55981000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9872000 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
46109000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5103000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
41006000 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
46109000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
43485000 usd
cdxs Allowance For Credit Loss Writeoff
AllowanceForCreditLossWriteoff
257000 usd
CY2022Q2 cdxs Allowance For Credit Loss Writeoff
AllowanceForCreditLossWriteoff
257000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2 segment
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38406000 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25453000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73746000 usd
CY2022Q1 cdxs Allowance For Credit Loss
AllowanceForCreditLoss
416000 usd
CY2021Q4 cdxs Allowance For Credit Loss
AllowanceForCreditLoss
416000 usd
CY2020Q4 cdxs Allowance For Credit Loss
AllowanceForCreditLoss
74000 usd
CY2021Q1 cdxs Allowance For Credit Loss
AllowanceForCreditLoss
74000 usd
CY2022Q2 cdxs Allowance For Credit Loss Expense Reversal
AllowanceForCreditLossExpenseReversal
0 usd
cdxs Allowance For Credit Loss Expense Reversal
AllowanceForCreditLossExpenseReversal
0 usd
cdxs Allowance For Credit Loss Expense Reversal
AllowanceForCreditLossExpenseReversal
0 usd
CY2021Q2 cdxs Allowance For Credit Loss Expense Reversal
AllowanceForCreditLossExpenseReversal
0 usd
cdxs Allowance For Credit Loss Writeoff
AllowanceForCreditLossWriteoff
0 usd
CY2021Q2 cdxs Allowance For Credit Loss Writeoff
AllowanceForCreditLossWriteoff
0 usd
cdxs Allowance For Credit Loss Adjustment
AllowanceForCreditLossAdjustment
50000 usd
CY2022Q2 cdxs Allowance For Credit Loss Adjustment
AllowanceForCreditLossAdjustment
50000 usd
CY2021Q2 cdxs Allowance For Credit Loss Adjustment
AllowanceForCreditLossAdjustment
0 usd
cdxs Allowance For Credit Loss Adjustment
AllowanceForCreditLossAdjustment
0 usd
CY2022Q2 cdxs Allowance For Credit Loss
AllowanceForCreditLoss
109000 usd
CY2021Q2 cdxs Allowance For Credit Loss
AllowanceForCreditLoss
74000 usd
CY2022Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
29200000 usd
CY2021Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
24953000 usd

Files In Submission

Name View Source Status
0001200375-22-000032-index-headers.html Edgar Link pending
0001200375-22-000032-index.html Edgar Link pending
0001200375-22-000032.txt Edgar Link pending
0001200375-22-000032-xbrl.zip Edgar Link pending
cdxs-20220630.htm Edgar Link pending
cdxs-20220630.xsd Edgar Link pending
cdxs-20220630_cal.xml Edgar Link unprocessable
cdxs-20220630_def.xml Edgar Link unprocessable
cdxs-20220630_htm.xml Edgar Link completed
cdxs-20220630_lab.xml Edgar Link unprocessable
cdxs-20220630_pre.xml Edgar Link unprocessable
cdxsgsktechnologycollabora.htm Edgar Link pending
cdxs_20220630xex311sp.htm Edgar Link pending
cdxs_20220630xex312sp.htm Edgar Link pending
cdxs_20220630xex321sp.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_0.jpg Edgar Link pending
image_52.jpg Edgar Link pending
image_68.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending